A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) Meeting Abstract


Authors: Younes, A.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Hong, X.; Zhu, J.; Samoilova, O.; Suh, C.; Matsumura, I.; Lopez-Hernandez, A.; Duhrsen, U.; Thieblemont, C.; Carey, J.; Liu, G.; Shreeve, S. M.; Sun, S.; Vermeulen, J.; Staudt, L. M.; Wilson, W. H.
Abstract Title: A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL)
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837602162
PROVIDER: wos
Notes: Meeting Abstract: 784 -- Source: Wos
MSK Authors
  1. Anas Younes
    203 Younes
Related MSK Work